119th Congress · introduced in the House · Dec 4, 2025
HELP Copays Act
Official title from Congress.gov
Latest action (Dec 4, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Health care costs and insurance
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
62 citations; showing the 25 most recently posted.
SANOFI US SERVICES INC · lobbying firm or registrant: SANOFI US SERVICES INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$1,250,000
Spent on own lobbying
…eral; Issues related to HR 1 One Big Beautiful Bill; HR 830 HELP Copays Act; HR2880 Protecting Patients Against PBM Abuse Act; HR 5376 Inflation Reduction Act; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS approp…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: THE KPM GROUP DC LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
HR 5509/S.2903 Safe Step Act HR 6423/S. 864 HELP Copays Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
EPILEPSY FOUNDATION · lobbying firm or registrant: EPILEPSY FOUNDATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$90,000
Spent on own lobbying
…428/H.R. 930, Stop the Wait Act, support passage -Requests to join the Congressional Epilepsy Caucus -S. 2903/H.R. 5509, Safe Step Act, support passage -S. 864/H.R. 6423, HELP Copays Act, support passage -WISeR Model, express concern with how it could impede access to some epilepsy treatments -PBM Reform, support legislative an…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$2,560,000
Spent on own lobbying
…s Act ---S.822: Scientific EXPERT Act ---Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products ---H.R.5509/S.2903:SAFE STEP Act ---S.864/H.R.6423: HELP Copays Act ---Access to Innovative Treatments ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Medicare Part B Physici…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$2,560,000
Spent on own lobbying
…sures ---WHO Pandemic Preparedness Accord Reimbursement and Coverage of Innovative Products ---H.R.6166: Lowering Drug Costs for American Families Act ---S.864/H.R.6423: HELP Copays Act ---CMMI Authority ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CYSTIC FIBROSIS FOUNDATION · lobbying firm or registrant: CYSTIC FIBROSIS FOUNDATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$170,000
Spent on own lobbying
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CYSTIC FIBROSIS FOUNDATION · lobbying firm or registrant: CYSTIC FIBROSIS FOUNDATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Insurance
$170,000
Spent on own lobbying
H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDIN…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$7,040,000
Spent on own lobbying
…the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Pat…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$1,530,000
Spent on own lobbying
…the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Pat…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALLIANCE FOR PATIENT ACCESS · lobbying firm or registrant: ALLIANCE FOR PATIENT ACCESS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$20,000
Spent on own lobbying
S. 1973 / H.R. 4231 Treat and Reduce Obesity Act of 2025 S. 864 / H.R. 6423HELP Copays Act H.R.4317 - PBM Reform Act of 2025 COPD awareness/funding Biomarker testing coverage S. 3267 ASAP Act H.R. 3267 Protecting Patient Access to Canc…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE ALS ASSOCIATION · lobbying firm or registrant: THE ALS ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$30,000
Spent on own lobbying
H.R. 7336/S.3763 - ALS Better Care Act - All provisions. H.R. 6423/S. 864 - HELP Copays Act -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's c…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$1,790,000
Spent on own lobbying
…hts Act to require that commercial health plans provide coverage of breast or wall reconstruction provided as part of breast cancer treatment. HELP Copays Act, H.R. 6423, S. 864. Bill would apply financial assistance towards the cost-sharing requirements of health insurance plans. Lung Cancer Screening and Prevention Act, H.R.1…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN G. KOMEN · lobbying firm or registrant: ARTEMIS POLICY GROUP LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Insurance
$40,000
Paid to lobbying firm
…ul Bill Act (H.R.1) Policies related to coverage for breast cancer treatments, including breast or chest wall surgical reconstructions HELP Copays Act (S. 864, H.R. 6423) Excepted Fertility Benefits Proposed Rules (1210-AC40)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VERTEX PHARMACEUTICALS INCORPORATED · lobbying firm or registrant: VERTEX PHARMACEUTICALS INCORPORATED
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$1,100,000
Spent on own lobbying
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General educ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE HEMOPHILIA ALLIANCE · lobbying firm or registrant: ARTEMIS POLICY GROUP LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Insurance
$30,000
Paid to lobbying firm
…lans: comments on essential health benefits review, RIN 0938-AW02 Policies related to co-pay accumulators and maximizers, including the HELP Copays Act (S 864, HR 6423) Policies related to the operations of pharmacy benefits managers Private insurance policies that discriminate coverage for high-cost drugs and use of patient…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CROHN'S & COLITIS FOUNDATION · lobbying firm or registrant: CROHN'S & COLITIS FOUNDATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$40,000
Spent on own lobbying
FY 2027 Funding for medical research at the NIH and CDC FY 2027 Appropriations - DoD Congressionally Directed Medical Research Program S 864/ HR 6423 Help Ensure Lower Patient Copays Act S 526 Pharmacy Benefit Manager Transparency Act HR 5509/ S 2903: Safe Step Act S 3304 / HR 5684 Medical Foods and Formula…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$80,000
Spent on own lobbying
H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles a…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: THE KPM GROUP DC LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · amended · posted Jul 28, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
HR 5509/S.2903 Safe Step Act HR 6423/S. 864 HELP Copays Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SANOFI US SERVICES INC · lobbying firm or registrant: SANOFI US SERVICES INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Health Issues
$920,000
Spent on own lobbying
…ations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS approp…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Health Issues
$2,360,000
Spent on own lobbying
…Rare Pediatric Disease Priority Review ---S.822: Scientific EXPERT Act ---Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products ---S.864/H.R.6423: HELP Copays Act ---S.1816: Improving Seniors Timely Access to Care Act of 2025 ---Access to Innovative Treatments ---Administrative Rebate Rule ---CMMI Author…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Medicare/Medicaid
$2,360,000
Spent on own lobbying
…) of 2022 ---Pediatric Priority Review Voucher Program Reauthorization Precision Medicine Initiative Reimbursement and Coverage of Innovative Products ---S.864/H.R.6423: HELP Copays Act ---CMMI Authority Vaccines and Infectious Diseases ---Adult Immunization ---Countermeasures Injury Compensation Program ---MCM Manufacturing &…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PATIENT ACCESS NETWORK FOUNDATION · lobbying firm or registrant: VENABLE LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$40,000
Paid to lobbying firm
Prohibiting copay accumulators in ACA Exchange plans: Help Ensure Lower Patient (HELP) Copays Act (H.R. 6423 / S. 864); Transparency and streamline utilization management protocols including prior authorization and step therapy, Safe Step Act, and Improving Senior's T…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CYSTIC FIBROSIS FOUNDATION · lobbying firm or registrant: CYSTIC FIBROSIS FOUNDATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$270,000
Spent on own lobbying
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BE…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CYSTIC FIBROSIS FOUNDATION · lobbying firm or registrant: CYSTIC FIBROSIS FOUNDATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Insurance
$270,000
Spent on own lobbying
H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BE…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$7,360,000
Spent on own lobbying
…the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R.…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing